A 10-mL Octreoscan Reaction Vial which contains a lyophilized mixture of:.A method recommended for determining the labeling yield is presented at the end of this package insert. In either case, the labeling yield of indium In-111 pentetreotide should be determined before administration to the patient. The indium In-111 pentetreotide solution is suitable for intravenous administration as is, or it may be diluted to a maximum volume of 3.0 mL with 0.9% Sodium Chloride Injection, U.S.P., immediately before intravenous administration. No bacteriostatic preservative is present.

The pH of the resultant indium In-111 pentetreotide solution is between 3.8 and 4.3. Indium In-111 reacts with the diethylenetriaminetetraacetic acid portion of the pentetreotide molecule to form indium In 111 pentetreotide. Indium In-111 pentetreotide is prepared by combining the two kit components (see INSTRUCTIONS FOR THE PREPARATION OF INDIUM In-111 PENTETREOTIDE). The vial contents are sterile and nonpyrogenic.

Prior to lyophilization, sodium hydroxide or hydrochloric acid may have been added for pH adjustment. Pentetreotide has the following structural formula: It is a kit consisting of two components: Octreoscan™ is a kit for the preparation of indium In-111 pentetreotide, a diagnostic radiopharmaceutical. What Are Side Effects of Octreoscan?ĭiagnostic - For Intravenous Use DESCRIPTION Patients who take long-acting somatostatin analogues (Sandostatin) should delay this test for 3-4 weeks after their last dose.Octreoscan ( indium in -111 pentetreotide kit) is a diagnostic agent used to locate cancerous tumors.

Physicians plan to use Netspot PET in order to diagnose neuroendocrine tumors, determine treatment options, plan surgery, and monitor for recurrence. In addition, finding NETs in this manner means the patient would likely be eligible for a new treatment, called Peptide Receptor Radionuclide Therapy (PRRT), that uses hormone-tagged radiation to find and attack the cancer cells. The improved image can help the oncologist choose optimal therapy, such as choosing surgery or systemic therapy. Because PET can be used, the physician gets a very clear, high-resolution image that can identify very small lesions that would otherwise be missed. Completed in a couple hours, this test is much quicker than the onerous three-day octreoscan (which uses a radioactive drug and a gamma camera to measure the radio material over time. This imaging approach significantly improves detection of NETs in three important ways: How is it better than current testing methods? Ga-68 dotatate is a radioactive lookalike of the hormone that binds to the somatostatin receptors, highlighting the tumor on PET imaging. While NETs don’t consume glucose like other cancers, their cells do have plenty of receptors for the hormone somatostatin, which regulates the endocrine system. (PET scans normally detect cancer by infusing patients with a glucose preparation and then identifying the body areas where glucose is being consumed or metabolized rapidly.)Ī new agent, gallium-68 dotatate (Netspot ®), recently FDA-approved and available at Roswell Park, can be used as a PET tracer instead of radiolabeled glucose to identify carcinoid tumors even very small lesions significantly better than any currently available imaging. Typical positron emission tomography (PET) scans are not effective in detecting carcinoid tumors, because unlike other cancers, NETs do not consume glucose rapidly. Neuroendocrine Tumor Survivor: Frank's Story

Netspot nuclear medicine 3 vials